perindopril trial summary

All type of heart failure: 2 trials - Lechat - PEP CHF

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Death from any cause or hospitalization for any reason	0.21 [0.01 4.46]	p=1.00	0	125	1	Lechat,
NYHA class improvement	2.03 [0.95 4.33]	p=1.00	0	125	1	Lechat,
death or severe congestive heart failure	no data
Long term death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,
hospitalisation for heart failure	0.64 [0.41 1.01]	p=1.00	0	850	1	PEP CHF,
All cause death	0.86 [0.45 1.66]	p=1.00	0	975	2	Lechat,PEP CHF,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Death from any cause or hospitalization for any reason	no data
NYHA class improvement	no data
death or severe congestive heart failure	no data
Long term death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,
hospitalisation for heart failure	0.64 [0.41 1.01]	p=1.00	0	850	1	PEP CHF,
All cause death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with preserved-LVEF heart failure : 1 trials - PEP CHF

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Death from any cause or hospitalization for any reason	no data
NYHA class improvement	no data
death or severe congestive heart failure	no data
Long term death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,
hospitalisation for heart failure	0.64 [0.41 1.01]	p=1.00	0	850	1	PEP CHF,
All cause death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 1 trials - PEP CHF

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Death from any cause or hospitalization for any reason	no data
NYHA class improvement	no data
death or severe congestive heart failure	no data
Long term death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,
hospitalisation for heart failure	0.64 [0.41 1.01]	p=1.00	0	850	1	PEP CHF,
All cause death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 1 trials - EUROPA

No demonstrated result

Cough by 406% (harmful effect)

suggested cardiovascular events by 19% (not demonstrated)

suggested Coronary event by 23% (not demonstrated)

suggested Non fatal MI by 22% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.81 [0.71 0.92]	p=0.04	0	12218	1	EUROPA,
Cardiovascular death	0.86 [0.72 1.04]	p=1.00	0	12218	1	EUROPA,
stroke (fatal and non fatal)	0.96 [0.73 1.27]	p=1.00	0	12218	1	EUROPA,
Coronary event	0.77 [0.66 0.89]	p=0.04	0	12218	1	EUROPA,
Coronary death	no data
cardiovascular death, MI, stroke	no data
Non fatal MI	0.78 [0.67 0.91]	p=0.04	0	12218	1	EUROPA,
Revascularization	0.96 [0.85 1.08]	p=1.00	0	12218	1	EUROPA,
All cause death	0.89 [0.77 1.03]	p=1.00	0	12218	1	EUROPA,
Cough	5.06 [3.46 7.41]	p=0.04	0	12218	1	EUROPA,
Hypotension	3.53 [2.06 6.05]	p=0.04	0	12218	1	EUROPA,
angiodema	no data
Adverse events leading to treatment discontinuation	1.10 [1.01 1.20]	p=0.04	0	12218	1	EUROPA,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Perindopril angiotensin-Converting Enzyme Inhibitors